Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection

Clinical and Experimental Immunology

Volumn 177, Issue 3, 2014, Pages 687-695

  Lind, K ^a   Svedin, E ^a   Utorova, R ^a   Stone, V M ^a   Flodstrom Tullberg M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti viral defence; Coxsackievirus; Enterovirus; Hepatocytes; Interferons

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; 2',5' OLIGOADENYLATE SYNTHETASE 2; DOUBLE STRANDED RNA; INTERLEUKIN 28A; INTERLEUKIN 29; MYXOVIRUS RESISTANCE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN 1; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER CELL; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VERY ELDERLY; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-VIRAL DEFENCE; COXSACKIEVIRUS; ENTEROVIRUS; HEPATOCYTES; INTERFERONS;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; ENTEROVIRUS B, HUMAN; FEMALE; GENE EXPRESSION; HEPATOCYTES; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED;

EID: 84904719872     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12368     Document Type: Article

References (36)

1. Knipe DM, Howley PM, Griffin DE etal., eds. Fields virology, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2007.
2. Lin TY, Kao HT, Hsieh SH etal. Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections. Pediatr Infect Dis J 2003; 22:889-894.
3. Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med 2009; 14:222-227.
4. Kotenko SV, Gallagher G, Baurin VV etal. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
5. Prokunina-Olsson L, Muchmore B, Tang W etal. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-171.
6. Sheppard P, Kindsvogel W, Xu W etal. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-68.
7. de Weerd NA, Nguyen T. The interferons and their receptors - distribution and regulation. Immunol Cell Biol 2012; 90:483-491.
8. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011; 23:583-590.
9. Lind K, Richardson SJ, Leete P, Morgan NG, Korsgren O, Flodstrom-Tullberg M. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. J Virol 2013; 87:7646-7654.
10. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86:23-32.
11. Liu JY, Wang SM, Chen IC, Yu CK, Liu CC. Hepatic damage caused by coxsackievirus B3 is dependent on age-related tissue tropisms associated with the coxsackievirus-adenovirus receptor. Pathog Dis 2013; 68:52-60.
12. Yen MH, Tsao KC, Huang YC etal. Viral load in blood is correlated with disease severity of neonatal coxsackievirus B3 infection: early diagnosis and predicting disease severity is possible in severe neonatal enterovirus infection. Clin Infect Dis 2007; 44:e78-81.
13. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 2004; 110:3540-3543.
14. Wessely R, Klingel K, Knowlton KU, Kandolf R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 2001; 103:756-761.
15. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol 2012; 12:636-648.
16. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol 2013; 93:377-385.
17. Doyle SE, Schreckhise H, Khuu-Duong K etal. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44:896-906.
18. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79:3851-3854.
19. Marcello T, Grakoui A, Barba-Spaeth G etal. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-1898.
20. Park H, Serti E, Eke O etal. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012; 56:2060-2070.
21. Thomas E, Gonzalez VD, Li Q etal. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142:978-988.
22. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, Schuetz EG. Use of human hepatocytes to study P450 gene induction. Methods Enzymol 1996; 272:388-401.
23. Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis 2011; 203:1784-1790.
24. Huhn MH, Hultcrantz M, Lind K, Ljunggren HG, Malmberg KJ, Flodstrom-Tullberg M. IFN-gamma production dominates the early human natural killer cell response to Coxsackievirus infection. Cell Microbiol 2008; 10:426-436.
25. Witte K, Gruetz G, Volk HD etal. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10:702-714.
26. Huber S. Host immune responses to coxsackievirus B3. Curr Top Microbiol Immunol 2008; 323:199-221.
27. Hultcrantz M, Huhn MH, Wolf M etal. Interferons induce an antiviral state in human pancreatic islet cells. Virology 2007; 367:92-101.
28. Hillyer P, Mane VP, Schramm LM etal. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 2012; 90:774-783.
29. Diaz-San Segundo F, Weiss M, Perez-Martin E etal. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology 2011; 413:283-292.
30. Chieux V, Chehadeh W, Harvey J, Haller O, Wattre P, Hober D. Inhibition of coxsackievirus B4 replication in stably transfected cells expressing human MxA protein. Virology 2001; 283:84-92.
31. Flodstrom-Tullberg M, Hultcrantz M, Stotland A etal. RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J Immunol 2005; 174:1171-1177.
32. Lowenstein CJ, Hill SL, Lafond-Walker A etal. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 1996; 97:1837-1843.
33. Shindo H, Maekawa S, Komase K etal. IL-28B (IFN-lambda3) and IFN-alpha synergistically inhibit HCV replication. J Viral Hepat 2013; 20:281-289.
34. Muir AJ, Shiffman ML, Zaman A etal. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52:822-832.
35. Ramos EL. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res 2010; 30:591-595.
36. Perez-Martin E, Weiss M, Diaz-San Segundo F etal. Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J Virol 2012; 86:4477-4487.